Request for Letters Rogatory Denied Due to Tardiness and Likely Delay to Trial Date

Dec 4, 2019

Reading Time : 2 min

The case began on July 19, 2018, when Luminati Networks Ltd. filed a complaint for patent infringement against UAB Tesonet (“Tesonet”). In its initial disclosures, Tesonet disclosed two witnesses who were on the board of directors of Luminati and also managing partners of EMK Capital, a non-party UK-based private equity fund that is an investor in Luminati.

The court issued a scheduling order setting September 16, 2019, as the close of fact discovery. On September 3, 2019, Tesonet and its codefendant filed a motion to compel Luminati to produce documents and emails from EMK. Following an October 1, 2019 hearing, the court denied the motion explaining that its ruling was based on Luminati’s representation that it had produced all relevant EMK documents in its possession. But the court added that Tesonet had leave to pursue discovery directly from EMK through the Hague Convention, in light of Tesonet’s representation that it would “not seek to change the trial date or any other deadline.”

On November 15, 2019, Tesonet moved the court to sign a Letter Rogatory. Tesonet stated that while Luminati opposed the motion based on a purported delay, the delay was caused by Tesonet’s need to retain U.K. counsel and to prepare a conforming Letter Rogatory. In response, Luminati argued first that Tesonet’s request was irreconcilable with its earlier statement to the court that it did not want a delay and would not ask for a delay on account of the overseas discovery request. Luminati then argued that Tesonet had not identified a specific need for EMK documents, nor had Tesonet explained how any documents could be admitted at trial when no EMK witnesses were identified on its trial witness list. Finally, Luminati argued that allowing the discovery would delay trial because a request to the U.K. would take between six and twelve months to complete, and that numerous pretrial deadlines had already passed, and Luminati would be highly prejudiced by any ensuing delay.

The court denied Tesonet’s motion and stated that it was “not convinced” that the trial date would hold if it allowed Tesonet to pursue the EMK discovery. The court also explained that it “seriously doubt[ed]” whether the discovery could be completed in time given that trial was two months away. Furthermore, the court found that Luminati would be prejudiced.

Luminati Networks Ltd. v. UAB Tesonet, 18-cv-00299, slip op. (E.D. Tex. Nov. 27, 2019) (Gilstrap, C.J.)

Practice Tip: Litigants contemplating discovery through the Hague Convention should prepare early in the discovery period and seek overseas counsel as early as possible to minimize delays in preparing suitable foreign discovery requests for the court’s approval.

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.